
An International Publisher for Academic and Scientific Journals
Author Login
Scholars Academic Journal of Pharmacy | Volume-14 | Issue-04
Pharmacovigilance in Unani Medicine
Afeefa Kazmi, Md. Tanwir Alam, Nauris Quamar, Mohd. Aleemuddin Quamri, Md. Razi Ahmad, Mariyam Jameel, Shabana Noor
Published: May 16, 2025 |
322
36
Pages: 65-74
Downloads
Abstract
Unani Medicine (Greek Medicine) is considered oldest and widely practiced medical system, India is home to this and it’s an integral part of Ayush. India is the home of Unani Medicine (Greek Medicine), which is the oldest and widely practiced kind of alternative medicine all through the ages. Everywhere, including in the Europe, Middle East, Central Asia, and the Indian subcontinent, it is being performed under various names. Pharmacovigilance in Ayush refers to the practice of monitoring and ensuring the safety of Ayurveda, Yoga, Unani, Siddha, and Homeopathy (Ayush) medicines. It involves the collection, detection, assessment, monitoring, and prevention of adverse effects or any other drug-related problems associated with the use of Ayush medicines. It aims to promote the safe and effective use of Ayush medicines by identifying and evaluating any potential risks or side effects. It involves the reporting and analysis of adverse drug reactions (ADRs) and other safety concerns related to Ayush medicines. Objectives of pharmacovigilance in Unani Medicine are to ensuring patient safety, improving the quality of Ayush medicines, and enhancing public health. Overall, pharmacovigilance in Unani Medicine plays a crucial role in ensuring the safety and effectiveness of Ayush medicines, thereby promoting their responsible use and protecting public health. Although Unani medicine's core principles date back hundreds of years, pharmacovigilance is a relatively recent concept. Its integration into the system will undoubtedly improve the standard of care we provide to the patients. The majority of medicines and regimens (Therapies/Regimenal therapies) used in Unani system of medicine are less supported by data yet; their three-dimensional impact and effect, as well as safety criteria, have not been assessed. As a result, there is a significant risk of adverse drug reactions and side effects associated with them. This pharmacovigilance program will assist in evaluating, identify